| Literature DB >> 35392484 |
Luna Liu1,2, Hai Wang2,3, Jing Ning1,2, Junming Han2,3, Chunxiao Yu1,2,3, Qingbo Guan1,2,3.
Abstract
Objectives: Peripheral artery disease (PAD) in diabetic populations is a vital chronic disease all over the world due to its high morbidity and mortality. It is important to find early simple screening biomarkers and find residual risk factors that may provide a new target for prevention and treatment of PAD in diabetic patients besides traditional cardiometabolic risk factors.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35392484 PMCID: PMC8983175 DOI: 10.1155/2022/5064264
Source DB: PubMed Journal: J Diabetes Res Impact factor: 4.011
Baseline characteristics of studied population.
| Characteristics | Non-PAD ( | PAD ( |
|
|---|---|---|---|
| Age (years) | 57.56 ± 11.83 | 68.04 ± 9.83 | <0.001 |
| Sex (male %) | 56.3 | 36.7 | <0.001 |
| BMI (kg/m2) | 25.60 ± 3.73 | 25.03 ± 4.17 | 0.114 |
| Diabetes course (years) | 9.84 ± 7.38 | 15.70 ± 9.11 | <0.001 |
| FPG (mmol/L) | 8.37 ± 2.85 | 8.62 ± 3.53 | 0.457 |
| HbA1C (%) | 8.85 ± 1.96 | 9.25 ± 2.10 | 0.034 |
| Insulin (uIU/ml) | 13.77 ± 36.59 | 20.87 ± 46.20 | 0.120 |
| C-P (ng/ml) | 1.95 ± 1.16 | 1.96 ± 1.42 | 0.974 |
| TG (mmol/L) | 1.76 ± 1.57 | 1.81 ± 1.30 | 0.741 |
| TC (mmol/L) | 4.97 ± 1.34 | 4.99 ± 1.23 | 0.891 |
| LDL-C (mmol/L) | 3.08 ± 0.95 | 3.07 ± 0.96 | 0.853 |
| HDL-C (mmol/L) | 1.19 ± 0.32 | 1.18 ± 0.28 | 0.782 |
| HCY (umol/L) | 12.25 ± 6.73 | 14.07 ± 9.22 | 0.006 |
| ALT (U/L) | 23.09 ± 20.29 | 16.99 ± 9.50 | <0.001 |
| AST (U/L) | 22.88 ± 15.92 | 19.83 ± 6.23 | <0.001 |
| RBC (1012/L) | 4.65 ± 0.57 | 4.34 ± 0.60 | <0.001 |
| WBC (109/L) | 6.46 ± 1.96 | 7.07 ± 2.55 | 0.011 |
| PLT (109/L) | 230.89 ± 64.83 | 249.32 ± 83.03 | 0.003 |
| Fib (g/l) | 3.10 ± 0.94 | 3.61 ± 1.16 | <0.001 |
| CRP (mg/L) | 6.23 ± 22.22 | 9.45 ± 27.70 | 0.207 |
| URIC (umol/L) | 330.71 ± 207.79 | 401.63 ± 577.26 | 0.183 |
| BUN (mmol/L) | 5.53 ± 3.17 | 6.46 ± 2.83 | 0.001 |
| CREA (umol/L) | 68.33 ± 145.68 | 72.94 ± 33.70 | 0.730 |
| eGFR | 100.35 ± 20.33 | 84.02 ± 22.82 | <0.001 |
| BMG (mg/L) | 2.12 ± 1.13 | 2.83 ± 1.31 | <0.001 |
| CysC (mg/L) | 0.94 ± 0.36 | 1.21 ± 0.48 | <0.001 |
| RBP (mg/L) | 42.46 ± 13.76 | 44.60 ± 15.68 | 0.106 |
| uMALB (mg/L) | 93.50 ± 357.50 | 220.00 ± 633.11 | 0.033 |
| uCREA (mmol/L) | 7.88 ± 4.87 | 5.53 ± 3.71 | <0.001 |
| uMALB/uCREA (mg/g) | 197.91 ± 969.01 | 483.03 ± 1186.63 | 0.013 |
| Hypertension (%) | 49.5 | 75.4 | <0.001 |
| CHD (%) | 22.5 | 42.4 | <0.001 |
| CVD (%) | 11.7 | 31.4 | <0.001 |
| Smoking status (%) | 0.048 | ||
| Never | 64.4 | 62.7 | |
| Ever | 14.6 | 8.5 | |
| Current | 21.0 | 28.8 | |
| Drinking status (%) | 0.003 | ||
| Never | 60.8 | 76.3 | |
| Ever | 10.2 | 8.5 | |
| Current | 29.0 | 15.3 |
Abbreviations: PAD: peripheral artery disease; BMI: body mass index; FPG: fasting blood glucose levels; HbA1C: glycosylated hemoglobin; TG: triglyceride; TC: total cholesterol; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; HCY: homocysteine; ALT: alanine aminotransferase; AST: aspartate aminotransferase; RBC: red blood cell; WBC: white blood cell; PLT: platelets; Fib: fibrinogen; CRP: C reactive protein; URIC: uric acid; BUN: urea nitrogen; CREA: creatinine; eGFR: estimated glomerular filtration rate; BMG: beta 2 microglobulin; CysC: cystatin C; RBP: retinol binding protein; uMALB: urine microalbumin; uCREA: urine creatinine; CHD: coronary heart disease; CVD: cerebrovascular disease.
Univariate logistic regression analysis between risk factors and PAD.
| Characteristics | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| Age (years) | Ref. | 1.308 (0.526-3.253) | 3.649 (1.717-7.757) | 11.237 (5.530-22.836) |
| Diabetes course (years) | Ref. | 1.783 (0.923-3.443) | 2.599 (1.290-5.235) | 5.346 (2.931-9.752) |
| HbA1C (%) | Ref. | 2.311 (1.251-4.272) | 2.646 (1.450-4.830) | 1.928 (1.026-3.623) |
| HCY (umol/L) | Ref. | 1.141 (0.608-2.140) | 1.697 (0.939-3.067) | 2.825 (1.633-4.888) |
| ALT (U/L) | Ref. | 0.605 (0.382-0.957) | 0.368 (0.214-0.632) | 0.285 (0.158-0.514) |
| RBC (1012/L) | Ref. | 0.575 (0.367-0.902) | 0.290 (0.167-0.503) | 0.198 (0.104-0.375) |
| WBC (109/L) | Ref. | 1.590 (0.891-2.839) | 1.576 (0.880-2.823) | 2.065 (1.183-3.605) |
| PLT (109/L) | Ref. | 1.141 (0.643-2.021) | 1.459 (0.847-2.515) | 1.640 (0.963-2.794) |
| Fib (g/L) | Ref. | 2.072 (1.022-4.200) | 3.142 (1.607-6.143) | 4.531 (2.373-8.652) |
| URIC (umol/L) | Ref. | 1.295 (0.746-2.246) | 1.346 (0.776-2.336) | 1.461 (0.850-2.510) |
| BUN (mmol/L) | Ref. | 1.493 (0.809-2.753) | 1.496 (0.807-2.773) | 3.099 (1.772-5.419) |
| CREA (umol/L) | Ref. | 1.086 (0.613-1.924) | 0.980 (0.544-1.766) | 2.194 (1.315-3.660) |
| eGFR | Ref. | 0.390 (0.248-0.612) | 0.172 (0.094-0.317) | 0.113 (0.053-0.237) |
| BMG (mg/L) | Ref. | 1.469 (0.673-3.204) | 2.739 (1.345-5.577) | 6.919 (3.595-13.316) |
| CysC (mg/L) | Ref. | 1.168 (0.517-2.636) | 3.865 (1.943-7.689) | 6.339 (3.279-12.254) |
| RBP (mg/L) | Ref. | 1.125 (0.641-1.973) | 1.496 (0.881-2.539) | 1.340 (0.780-2.304) |
| uMALB (mg/L) | Ref. | 1.248 (0.649-2.401) | 1.448 (0.766-2.738) | 3.751 (2.142-6.568) |
| uCREA (mmol/L) | Ref. | 0.597 (0.375-0.951) | 0.384 (0.226-0.651) | 0.195 (0.100-0.380) |
| uMALB/uCREA (mg/g) | Ref. | 2.715 (1.188-6.204) | 3.830 (1.729-8.484) | 8.164 (3.841-17.352) |
Abbreviations: PAD: peripheral artery disease; Q: quartile; Ref.: reference; HbA1C: glycosylated hemoglobin; HCY: homocysteine; ALT: alanine aminotransferase; RBC: red blood cell; WBC: white blood cell; PLT: platelets; Fib: fibrinogen; URIC: uric acid; BUN: urea nitrogen; CREA: creatinine; eGFR: estimated glomerular filtration rate; BMG: beta 2 microglobulin; CysC: cystatin C; RBP: retinol binding protein; uMALB: urine microalbumin; uCREA: urine creatinine.
Figure 1ROC curve of potential risk factors to predict PAD. Abbreviations: ROC: receiver operating characteristic; PAD: peripheral artery disease; eGFR: estimated glomerular filtration rate; CysC: cystatin C; BMG: beta 2 microglobulin.
AUCs, cut-off, sensitivity, and specificity of risk factors in ROC analysis to predict PAD.
| Characteristics | AUC | 95% CI | Cut-off | Sensitivity | Specificity | Youden index |
|---|---|---|---|---|---|---|
| eGFR | 0.728 | 0.682-0.773 | 95.500 | 0.692 | 0.678 | 0.369 |
| CysC (mg/L) | 0.716 | 0.669-0.762 | 0.915 | 0.767 | 0.594 | 0.360 |
| BMG (mg/L) | 0.713 | 0.665-0.761 | 2.240 | 0.633 | 0.720 | 0.353 |
| Diabetes course (years) | 0.688 | 0.638-0.738 | 11.500 | 0.644 | 0.638 | 0.282 |
| RBC (1012/L) | 0.668 | 0.619-0.717 | 4.455 | 0.617 | 0.671 | 0.288 |
| uCREA (mg/L) | 0.663 | 0.614-0.711 | 5.840 | 0.704 | 0.581 | 0.286 |
| uMALB (mmol/L) | 0.649 | 0.596-0.702 | 21.380 | 0.479 | 0.768 | 0.247 |
| BUN (mmol/L) | 0.616 | 0.562-0.670 | 6.550 | 0.392 | 0.798 | 0.190 |
| CREA (umol/L) | 0.581 | 0.523-0.638 | 73.400 | 0.383 | 0.789 | 0.173 |
| WBC (109/L) | 0.574 | 0.520-0.628 | 8.975 | 0.225 | 0.913 | 0.138 |
| PLT (109/L) | 0.563 | 0.510-0.616 | 206.500 | 0.742 | 0.371 | 0.113 |
| RBP (mg/L) | 0.541 | 0.489-0.593 | 42.350 | 0.533 | 0.563 | 0.097 |
Abbreviations: AUC: area under curve; ROC: receiver operating characteristic; PAD: peripheral artery disease; 95% CI: 95% credibility interval; eGFR: estimated glomerular filtration rate; CysC: cystatin C; BMG: beta 2 microglobulin; RBC: red blood cell; uCREA: urine creatinine; uMALB: urine microalbumin; BUN: urea nitrogen; CREA: creatinine; WBC: white blood cell; PLT: platelets; RBP: retinol binding protein.
Main risk factors associated with increased risk of developing PAD.
| Risk factor | OR (95% CI) |
| Regression coefficient | Risk points |
|---|---|---|---|---|
| Age | 1.075 (1.049-1.102) | <0.001 | 0.073 | 1 |
| Smoking status | ||||
| Never | 1.00 | 0 | ||
| Ever | 1.233 (0.528-2.881) | 0.629 | 0.209 | 3 |
| Current | 6.040 (3.126-11.672) | <0.001 | 1.798 | 25 |
| Sex | ||||
| Male | 1.00 | 0 | ||
| Female | 2.866 (1.571-5.227) | 0.001 | 1.053 | 14 |
| WBC (109/L) | ||||
| <8.975 | 1.00 | 0 | ||
| ≥8.975 | 2.856 (1.673-4.873) | <0.001 | 1.049 | 14 |
| CysC (mg/L) | ||||
| <0.915 | 1.00 | 0 | ||
| ≥0.915 | 2.497 (1.535-4.064) | <0.001 | 0.915 | 13 |
| RBC (1012/L) | ||||
| ≥4.455 | 1.00 | 0 | ||
| <4.455 | 2.090 (1.334-3.276) | 0.001 | 0.737 | 10 |
| Diabetic course (years) | ||||
| <11.5 | 1.00 | 0 | ||
| ≥11.5 | 1.667 (1.078-2.577) | 0.021 | 0.511 | 7 |
| PLT (109/L) | ||||
| <206.500 | 1.00 | 0 | ||
| ≥206.500 | 1.771 (1.097-2.859) | 0.019 | 0.572 | 8 |
Main risk factors associated with increased risk of developing PAD. This table used the stepwise logistic regression analysis to find the independent risk factor for developing of PAD. The risk factors used in stepwise logistic regression analysis included age, sex, CysC, PLT, WBC, RBC, diabetes course, smoking status, urea nitrogen, beta 2 microglobulin, estimated glomerular filtration rate, homocysteine, fibrinogen, and alanine aminotransferase. We chose an entry probability of <0.05 by the stepwise selection method. The risk points of each significantly associated risk factors are created by dividing the regression coefficient of each risk factor by the selected constant (regression coefficient of age) and then rounded to the nearest integer. One risk point equals the risk of developing PAD with each year increase in age in this population. To assess the PAD risk associated with combined exposure, a combined exposure score was obtained by summing the individual risk points for each participant. Abbreviations: WBC: white blood cell; CysC: cystatin C; RBC: red blood cell; PLT: platelets.
Figure 2The odds ratio of developing PAD among the quintiles of the combined exposure score. The odds ratio of developing PAD among the quintiles of the combined exposure score. Combined exposure score was obtained based on risk points of age, sex, smoking status, diabetic course, platelets (PLT), red blood cell (RBC), white blood cell (WBC), and cystatin C (CysC). Combined exposure score excluded CysC was calculated based on risk points of age, sex, smoking status, diabetic course, PLT, RBC, and WBC.
Figure 3Decision curve analysis of the two prediction models. X-axis indicates the threshold probability for critical care outcome, and Y-axis indicates the net benefit. Blue line = conventional model based on age, sex, smoking status, diabetic course, platelets (PLT), red blood cell (RBC), and white blood cell (WBC) and red line = complex model based on age, sex, smoking status, diabetic course, PLT, RBC, WBC, and cystatin C.